Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  American Journal of Obstetrics and Gynecology

• Publication date

  2008-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ajog.2008.01.005PMID 18395030PMCID PMC2532696
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The distal fallopian tube: a new model for pelvic serous carcinogenesis

  2007cited by this paper
• Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/Pten signaling pathways.

  2007cited by this paper
• Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate than previously reported and does not correlate with drug resistance

  2007cited by this paper
• Intraepithelial Carcinoma of the Fimbria and Pelvic Serous Carcinoma: Evidence for a Causal Relationship

  2007cited by this paper
• BEAMing: single-molecule PCR on microparticles in water-in-oil emulsions

  2006cited by this paper
• Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms

  2006cited by this paper
• BEAMing up for detection and quantification of rare sequence variants

  2006cited by this paper
• KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants.

  2006cited by this paper
• Molecular genetic evidence that endometriosis is a precursor of ovarian cancer

  2006cited by this paper
• Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation.

  2006cited by this paper
• SEER Cancer Statistics Review, 1975-2003

  2006cited by this paper
• SEER Cancer Statistics Review, 1975-2003, National Cancer Institute. Bethesda, MD,

  2006cited by this paper
• Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer

  2005cited by this paper
• Amplification of a chromatin remodeling gene, Rsf-1/HBXAP, in ovarian carcinoma.

  2005cited by this paper
• Mutations of BRAF and KRAS Precede the Development of Ovarian Serous Borderline Tumors

  2004cited by this paper
• In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low‐grade serous tumours

  2004cited by this paper
• Cancer genes and the pathways they control

  2004cited by this paper
• Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis.

  2004cited by this paper
• Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma.

  2003cited by this paper
• K-ras alterations in Danish ovarian tumour patients. From the Danish "Malova" Ovarian Cancer study.

  2003cited by this paper
• p53 mutations and overexpression affect prognosis of ovarian endometrioid cancer but not clear cell cancer.

  2003cited by this paper
• Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations

  2003cited by this paper
• Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma.

  2003cited by this paper
• Malignant mullerian mixed tumor arising from ovarian serous carcinoma: a clinicopathologic and molecular study of two cases.

  2002cited by this paper
• Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis.

  2002cited by this paper
• Diverse tumorigenic pathways in ovarian serous carcinoma.

  2002cited by this paper
• Perspectives on the development of a molecularly targeted agent.

  2002cited by this paper
• Analysis of the TGFβ functional pathway in epithelial ovarian carcinoma

  2001cited by this paper
• Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer

  2001cited by this paper
• &bgr;-Catenin Expression Pattern, &bgr;-Catenin Gene Mutations, and Microsatellite Instability in Endometrioid Ovarian Carcinomas and Synchronous Endometrial Carcinomas

  2001cited by this paper
• Diverse mechanisms of beta-catenin deregulation in ovarian endometrioid adenocarcinomas.

  2001cited by this paper
• Microsatellite instability, MLH‐1 promoter hypermethylation, and frameshift mutations at coding mononucleotide repeat microsatellites in ovarian tumors

  2001cited by this paper
• Allelic imbalance and mutations of the PTEN gene in ovarian cancer

  2000cited by this paper
• Heritability and molecular genetic studies of endometriosis.

  2000cited by this paper
• Common Genetic Changes between Endometriosis and Ovarian Cancer

  2000cited by this paper
• Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary.

  2000cited by this paper
• Bcl-2 and p53 protein expression, apoptosis, and p53 mutation in human epithelial ovarian cancers.

  2000cited by this paper
• Molecular Genetic Defects in Endometriosis

  2000cited by this paper
• Comparison of mutations of Ki-RAS and p53 immunoreactivity in borderline and malignant epithelial ovarian tumors.

  1999cited by this paper
• p53 mutations and expression in ovarian cancers: correlation with overall survival.

  1999cited by this paper
• Carcinosarcomas (malignant mixed mullerian tumors) of the female genital tract: comparative molecular analysis of epithelial and mesenchymal components.

  1998cited by this paper
• K‐ras mutations in nonmucinous ovarian epithelial tumors

  1998cited by this paper
• Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors.

  1998cited by this paper
• Molecular genetic evidence for the conversion hypothesis of the origin of malignant mixed Müllerian tumours

  1997cited by this paper
• Human ovarian cancer of the surface epithelium.

  1997cited by this paper
• The genetic analysis of ovarian cancer.

  1995cited by this paper
• Microsatellite instability and alterations in the HMSH2 gene in human ovarian cancer

  1995cited by this paper
• Mutation of K-ras protooncogene is associated with histological subtypes in human mucinous ovarian tumors.

  1994cited by this paper
• Mutation of K-ras protooncogene in human ovarian epithelial tumors of borderline malignancy.

  1993cited by this paper
• Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer.

  1993cited by this paper
• p53 gene mutations and protein accumulation in human ovarian cancer.

  1993cited by this paper
• Tumor suppressor p53: analysis of wild-type and mutant p53 complexes

  1991cited by this paper
• K-ras activation occurs frequently in mucinous adenocarcinomas and rarely in other common epithelial tumors of the human ovary.

  1991cited by this paper

• Increased IGF2 and Immunosuppressive Cell Populations in Ascites of Patients with Recurrent High-Grade Serous Ovarian Cancer

  2025cites this paper
• Applications of Nanoparticles in the Diagnosis and Treatment of Ovarian Cancer

  2025cites this paper
• Liquid Biopsy-Based Smart Sensors for Ovarian Cancer Detection.

  2025cites this paper
• Borderline ovarian tumours: A comprehensive review of published evidence.

  2025cites this paper
• Metal organic frameworks (MOFs)-based fluorescent CA125 analysis: A comparative study of the quenching effects of MIL-101, Cu-MOF, ZIF-8, UiO-66

  2024cites this paper
• Emerging role of mucins in antibody drug conjugates for ovarian cancer therapy

  2024cites this paper
• The Role of Cancer Stem Cell Markers in Ovarian Cancer

  2023cites this paper
• Metabolic and senescence characteristics associated with the immune microenvironment in ovarian cancer

  2023cites this paper
• Ovarian, Uterine, and Vulvovaginal Cancers: Screening, Treatment Overview, and Prognosis.

  2023cites this paper
• A Study on P16 Expression in Surface Epithelial Tumours of Ovary

  2022cites this paper
• A comparison of deep neural network models for cluster cancer patients through somatic point mutations

  2022cites this paper
• Ultra-radical (extensive) surgery versus standard surgery for the primary cytoreduction of advanced epithelial ovarian cancer.

  2022cites this paper
• Clinico-Immunohistochemical Analysis of Ovarian Tumors in a South Indian Population: A Single-Center Study

  2022cites this paper
• Ovarian Cancer Metastasis to Lung Parenchyma without Peritoneal Dissemination: A Rare Case

  2022cites this paper
• A benchmarking of deep neural network models for cancer subtyping using single point mutations

  2022cites this paper
• Identification of a Novel Tumor Microenvironment Prognostic Signature for Advanced-Stage Serous Ovarian Cancer

  2021cites this paper
• Ovarian tumor: a review

  2021cites this paper
• High-grade ovarian cancer associated H/ACA snoRNAs promote cancer cell proliferation and survival

  2021cites this paper
• Ovarian-Cancer-Associated Extracellular Vesicles: Microenvironmental Regulation and Potential Clinical Applications

  2021cites this paper
• Disease-Specific Survival of Type I and Type II Epithelial Ovarian Cancers—Stage Challenges Categorical Assignments of Indolence & Aggressiveness

  2020cites this paper
• CA125 and Ovarian Cancer: A Comprehensive Review

  2020cites this paper
• Factors in Oncogenesis: Viral Infections in Ovarian Cancer

  2020cites this paper
• A Comprehensive Molecular and Clinical Analysis of the piRNA Pathway Genes in Ovarian Cancer

  2020cites this paper
• Eukaryotic Initiation Factor 5A2 (EIF5A2) Contributes to Ovarian Tumor Growth and Metastasis

  2020cites this paper
• Extremely Late Recurrence of Ovarian Carcinoma Diagnosed by an Endoscopic Ultrasound-guided Fine-needle Biopsy

  2020cites this paper
• Ovarian cancer stem cells and targeted therapy

  2019cites this paper
• The biodiversity Composition of Microbiome in Ovarian Carcinoma Patients

  2019cites this paper
• GYN ONCOLOGY

  2019cites this paper
• Discovery of Furanone-Based Radiopharmaceuticals for Diagnostic Targeting of COX-1 in Ovarian Cancer

  2019cites this paper
• Comparison of Primary Tumor Size in Stage I and III Epithelial Ovarian Cancer

  2018cites this paper
• Overview of CD24 as a new molecular marker in ovarian cancer

  2018cites this paper
• THE DIFFERENCE BETWEEN HE4 EXPRESSION IN URINE OF WOMEN WITH OVARIAN CYST AND WOMEN WITH NORMAL OVARY

  2018cites this paper
• MSC stimulate ovarian tumor growth during intercellular communication but reduce tumorigenicity after fusion with ovarian cancer cells

  2018cites this paper
• Polarization-resolved second harmonic generation imaging of human ovarian cancer

  2018cites this paper
• Variant 4: Ovarian cancer screening. Postmenopausal. High risk (personal history or family history or

  2017influential citation
• Variant 4: Ovarian cancer screening. Postmenopausal. High risk (personal history or family history or

  2017influential citation
• MicroRNA‑146a‑5p enhances cisplatin‑induced apoptosis in ovarian cancer cells by targeting multiple anti‑apoptotic genes.

  2017cites this paper
• Management of Borderline Ovarian Tumors—Still a Gray Zone

  2017cites this paper
• Prognostic significance of MAPK, Topo IIα and E-cadherin immunoexpression in ovarian serous carcinomas.

  2017cites this paper
• Variant 4: Ovarian cancer screening. Postmenopausal. High risk (personal history or family history or known or suspected genetic predisposition or elevated CA-125).

  2017influential citation
• Variant 4: Ovarian cancer screening. Postmenopausal. High risk (personal history or family history or

  2017influential citation
• Notch3 Signaling Promotes Adhesion and Tumor Progression in a Murine Epithelial Ovarian Cancer Model

  2017cites this paper
• Correlación entre la clínica, ecografía, marcadores tumorales y bipsia intraoperatoria y definitiva en tumoraciones ováricas sospechosas de malignidad

  2017cites this paper
• The use of natural compounds for the targeting and chemoprevention of ovarian cancer.

  2017cites this paper
• Sorafenib controls the epithelial-mesenchymal transition of ovarian cancer cells via EGF and the CD44-HA signaling pathway in a cell type-dependent manner

  2017cites this paper
• Variant 4: Ovarian cancer screening. Postmenopausal. High risk (personal history or family history or

  2017cites this paper
• Variant 4: Ovarian cancer screening. Postmenopausal. High risk (personal history or family history or known or suspected genetic predisposition or elevated CA-125).

  2017influential citation
• Phytochemicals in the treatment of ovarian cancer.

  2017cites this paper
• Prognostic significance of lymphadenectomy and prevalence of lymph node metastasis in clinically-apparent stage I endometrioid and mucinous ovarian carcinoma.

  2017cites this paper
• Stromal alterations in ovarian cancers via wavelength dependent Second Harmonic Generation microscopy and optical scattering

  2017cites this paper
• Immunohistochemical analysis of expression of Estrogen Receptor on surface epithelial ovarian neoplasms and its role as a prognostic marker in them

  2017cites this paper
• Secretion of cytokines and heat shock protein (HspA1A) by ovarian cancer cells depending on the tumor type and stage of disease

  2017cites this paper
• Variant 4: Ovarian cancer screening. Postmenopausal. High risk (personal history or family history or known or suspected genetic predisposition or elevated CA-125).

  2017influential citation
• ACR Appropriateness Criteria® Ovarian Cancer Screening.

  2017cites this paper
• Variant 4: Ovarian cancer screening. Postmenopausal. High risk (personal history or family history or known or suspected genetic predisposition or elevated CA-125).

  2017influential citation
• Estimating Cost-effectiveness of a Multimodal Ovarian Cancer Screening Program in the United States: Secondary Analysis of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)

  2017cites this paper
• Ovarian Surface Epithelial Tumor Incidence in Tertiary Care Hospital in Andhra Pradesh

  2017cites this paper
• Variant 4: Ovarian cancer screening. Postmenopausal. High risk (personal history or family history or

  2017cites this paper
• Assessing local stromal alterations in human ovarian cancer subtypes via second harmonic generation microscopy and analysis

  2017cites this paper
• Detection of phosphatidylserine-positive exosomes as a diagnostic marker for ovarian malignancies: a proof of concept study

  2017cites this paper
• Orientation of Preclinical Research in Ovarian Cancer

  2017cites this paper
• Clonal composition of human ovarian cancer based on copy number analysis reveals a reciprocal relation with oncogenic mutation status.

  2017cites this paper
• Inflammation and Nitrosative Stress Effects in Ovarian and Prostate Pathology and Carcinogenesis

  2017cites this paper
• Variant 4: Ovarian cancer screening. Postmenopausal. High risk (personal history or family history or known or suspected genetic predisposition or elevated CA-125).

  2017influential citation
• The Value of Ultrasound Monitoring of Adnexal Masses for Early Detection of Ovarian Cancer

  2016cites this paper
• The effects of hyperglycemia on glucose metabolism in epithelial ovarian cancer

  2016cites this paper
• Plakoglobin Reduces the in vitro Growth, Migration and Invasion of Ovarian Cancer Cells Expressing N-Cadherin and Mutant p53

  2016cites this paper
• Prevalence of Chlamydia trachomatis and Mycoplasma genitalium in Patients with Benign and Malignant Ovarian Cancer by Nested PCR Method

  2016cites this paper
• Correlation Between Expressions of VEGF and CA-125 with Stage, Level of Differentiation and Histopathology Type of Epithelial Ovarian Cancer

  2016cites this paper
• Clinicopathological Study of Surface Epithelial Tumours of the Ovary: An Institutional Study.

  2016cites this paper
• Um novo modelo de carcinogénese para cancro do ovário: implicações clínicas da salpingectomia profiláctica

  2016cites this paper
• Expression signature distinguishing two tumour transcriptome classes associated with progression-free survival among rare histological types of epithelial ovarian cancer

  2016cites this paper
• Title Expression signature distinguishing two tumour transcriptome classes associated with progression-free survival among rare histological types of epithelial ovarian cancer

  2016cites this paper
• Solid lipid nanoparticles a tool combating Ovarian Cancer

  2016cites this paper
• Management of borderline ovarian tumors.

  2016cites this paper
• Genetically‐defined ovarian cancer mouse models

  2016cites this paper
• Gr upSM The Molecular Landscape of Different Ovarian Cancer Subtypes and New Prospects

  2016cites this paper
• DeepGene: an advanced cancer type classifier based on deep learning and somatic point mutations

  2016cites this paper
• Differences in Clinical and Biological Features Between Type I and Type II Tumors in FIGO Stages I-II Epithelial Ovarian Carcinoma

  2015cites this paper
• The Extracellular Matrix in Epithelial Ovarian Cancer – A Piece of a Puzzle

  2015cites this paper
• Colony-Stimulating Factor-1 Receptor Inhibition Reverses the Vascular Leakage that Causes Malignant Ascites in Late-Stage Epithelial Ovarian Cancer

  2015cites this paper
• Electronic Theses and Dissertations

  2015cites this paper
• Determination of the spectral dependence of reduced scattering and quantitative second-harmonic generation imaging for detection of fibrillary changes in ovarian cancer

  2015cites this paper
• c-Met inhibitors attenuate tumor growth of small cell hypercalcemic ovarian carcinoma (SCCOHT) populations

  2015cites this paper
• The role of free beta subunit of human chorionic gonadotropin in high-grade serous cancer

  2015cites this paper
• Strategic Steps for Advanced Molecular Imaging with Magnetic Resonance-Based Diagnostic Modalities

  2015cites this paper
• How the fast Padé transform handles noise for MRS data from the ovary: importance for ovarian cancer diagnostics

  2015cites this paper
• [Corrigendum] Metastasis suppressor 1 expression in human ovarian cancer: The impact on cellular migration and metastasis

  2015cites this paper
• The role of S100A14 in epithelial ovarian tumors

  2014cites this paper
• Oncogenic Fli-1 is a potential prognostic marker for the progression of epithelial ovarian cancer

  2014cites this paper
• Differential microRNA expression by Solexa sequencing in the sera of ovarian cancer patients.

  2014cites this paper
• Correlation Between E-cadherin Immunoexpression and Efficacy of First Line Platinum-Based Chemotherapy in Advanced High Grade Serous Ovarian Cancer

  2014cites this paper
• Ovarian cancer: An ever challenging malady

  2014cites this paper
• The Expression of Ribonucleotide Reductase M2 in the Carcinogenesis of Uterine Cervix and Its Relationship with Clinicopathological Characteristics and Prognosis of Cancer Patients

  2014cites this paper
• Quantitative Analysis of &ggr;-H2AX and p53 Nuclear Expression Levels in Ovarian and Fallopian Tube Epithelium from Risk-reducing Salpingo-Oophorectomies in BRCA1 and BRCA2 Mutation Carriers

  2014cites this paper
• Targeted treatment of ovarian cancer--the multiple - kinase - inhibitor sorafenib as a potential option.

  2014cites this paper
• Recent Concepts of Ovarian Carcinogenesis: Type I and Type II

  2014cites this paper
• ROLE OF ULTRASOUND IN EVALUATION OF PELVIC MASS

  2014cites this paper
• The expression of miR-30a* and miR-30e* is associated with a dualistic model for grading ovarian papillary serious carcinoma.

  2014cites this paper
• Gynaecological cancer symptoms: influences on women’s awareness and medical help-seeking

  2014cites this paper